- Home
- EML vs FBLG Comparison
EML vs FBLG Comparison
Compare EML & FBLG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EML
- FBLG
- Stock Information
- Founded
- EML 1858
- FBLG 2021
- Country
- EML United States
- FBLG United States
- Employees
- EML N/A
- FBLG N/A
- Industry
- EML Industrial Machinery/Components
- FBLG
- Sector
- EML Consumer Discretionary
- FBLG
- Exchange
- EML Nasdaq
- FBLG NYSE
- Market Cap
- EML 171.1M
- FBLG 163.3M
- IPO Year
- EML N/A
- FBLG 2024
- Fundamental
- Price
- EML $29.87
- FBLG $2.60
- Analyst Decision
- EML
- FBLG Strong Buy
- Analyst Count
- EML 0
- FBLG 1
- Target Price
- EML N/A
- FBLG $16.00
- AVG Volume (30 Days)
- EML 36.0K
- FBLG 309.9K
- Earning Date
- EML 08-06-2024
- FBLG 11-02-2024
- Dividend Yield
- EML 1.47%
- FBLG N/A
- EPS Growth
- EML 65.47
- FBLG N/A
- EPS
- EML 1.92
- FBLG N/A
- Revenue
- EML $273,702,675.00
- FBLG N/A
- Revenue This Year
- EML N/A
- FBLG N/A
- Revenue Next Year
- EML N/A
- FBLG N/A
- P/E Ratio
- EML $15.51
- FBLG N/A
- Revenue Growth
- EML N/A
- FBLG N/A
- 52 Week Low
- EML $16.10
- FBLG $1.08
- 52 Week High
- EML $35.78
- FBLG $46.00
- Technical
- Relative Strength Index (RSI)
- EML 54.35
- FBLG N/A
- Support Level
- EML $29.30
- FBLG N/A
- Resistance Level
- EML $31.35
- FBLG N/A
- Average True Range (ATR)
- EML 1.00
- FBLG 0.00
- MACD
- EML -0.06
- FBLG 0.00
- Stochastic Oscillator
- EML 47.67
- FBLG 0.00
About EML Eastern Company (The)
The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to industrial markets. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It operates in the United States and Other Countries and generates the majority of its revenue from the United States.
About FBLG FIBROBIOLOGICS INC
FibroBiologics Inc is a clinical-stage cell therapy company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including degenerative disc disease, multiple sclerosis, wound healing, and certain cancers, and potential extension of life applications including thymic and splenic involution reversal.